Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[Acadia Pharmaceuticals Inc.](/topic/$acad)

### Sentiment: XXX%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$acad/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$acad/time-series/sentiment.tsv)  
**Current Value**: XXX%  
**Daily Average**: XX%  
**1 Week**: XXX% no change  
**1 Month**: XXX% +62%  
**6 Months**: XXX% no change  
**1 Year**: XXX% +25%  
**1-Year High**: XXX% on 2024-10-31  
**1-Year Low**: XX% on 2025-02-01  

**Most Supportive Themes**
- **Positive Clinical Trial Results and Executive Appointment:** (45%) Acadia Pharmaceuticals ($ACAD) announced positive Phase X trial results for trofinetide in Rett syndrome and appointed a new Senior Vice President.
- **Analyst Upgrades and Price Momentum:** (30%) Strong earnings and analyst upgrades have driven $ACAD to a 52-week high.
  
**Most Critical Themes**
- **Market Volatility:** (10%)  The stock has experienced price fluctuations, with a 24-hour change of -XXXX% and varying performance over longer periods.
  
Network engagement breakdown:  
| Network | Positive | %  | Neutral | %   | Negative | %  |
| ------- | -------- | -  | ------- | -   | -------- | -  |
| X       | XX       | X% | XXX     | XX% | X        | X% |
| Reddit  | XX       | X% | X       | X%  | X        | X% |
|         |          |    |         |     |          |    |
| Total   | XX       | X% | XXX     | XX% | X        | X% |

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

Acadia Pharmaceuticals Inc.

Sentiment: XXX%

Sentiment Line Chart
Sentiment 24-Hour Time-Series Raw Data
Current Value: XXX%
Daily Average: XX%
1 Week: XXX% no change
1 Month: XXX% +62%
6 Months: XXX% no change
1 Year: XXX% +25%
1-Year High: XXX% on 2024-10-31
1-Year Low: XX% on 2025-02-01

Most Supportive Themes

  • Positive Clinical Trial Results and Executive Appointment: (45%) Acadia Pharmaceuticals ($ACAD) announced positive Phase X trial results for trofinetide in Rett syndrome and appointed a new Senior Vice President.
  • Analyst Upgrades and Price Momentum: (30%) Strong earnings and analyst upgrades have driven $ACAD to a 52-week high.

Most Critical Themes

  • Market Volatility: (10%) The stock has experienced price fluctuations, with a 24-hour change of -XXXX% and varying performance over longer periods.

Network engagement breakdown:

Network Positive % Neutral % Negative %
X XX X% XXX XX% X X%
Reddit XX X% X X% X X%
Total XX X% XXX XX% X X%
Acadia Pharmaceuticals Inc. (ACAD) Sentiment
/topic/$acad/sentiment